Immunovia AB (publ)
STO:IMMNOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immunovia AB (publ)
STO:IMMNOV
|
SE |
|
H & M Hennes & Mauritz AB
STO:HM B
|
SE |
|
Nexus Infrastructure PLC
LSE:NEXS
|
UK |
|
Z
|
Zhangjiagang Freetrade Science & Technology Group Co Ltd
SSE:600794
|
CN |
|
E
|
Eng Kah Corporation Bhd
KLSE:ENGKAH
|
MY |
|
T
|
TKD Science and Technology Co Ltd
SSE:603738
|
CN |
|
A
|
Alok Industries Ltd
NSE:ALOKINDS
|
IN |
|
P
|
PNG Copper Inc
CNSX:PNGC
|
CA |
Immunovia AB (publ)
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. The company is headquartered in Lund, Skane and currently employs 65 full-time employees. The company went IPO on 2015-12-01. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. The company is headquartered in Lund, Skane and currently employs 65 full-time employees. The company went IPO on 2015-12-01. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
